Ankylosing Spondylitis Market Size- By Drug Class, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Ankylosing Spondylitis Market Introduction and Overview

According to SPER market research, 'Ankylosing Spondylitis Market Size- By Drug Class, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Ankylosing Spondylitis Market is predicted to reach 11.75 billion by 2034 with a CAGR of 6.66%.

Ankylosing spondylitis (AS) is a chronic inflammatory illness mostly affecting the spine and sacroiliac joints, causing pain, stiffness, and progressive vertebral fusion. It is characterized as axial spondyloarthritis and is often related with the HLA-B27 genetic marker. AS primarily affects young adults, with symptoms beginning in late adolescence or early adulthood. Over time, inflammation can cause vertebrae to fuse, resulting in diminished spinal flexibility and a stooped posture.

Restraints: One of the most significant obstacles is the high expense of biologic medicines such as TNF inhibitors and IL-17 inhibitors, which makes treatment inaccessible for many patients, particularly those in low- and middle-income countries. Furthermore, delayed identification due to the non-specific early symptoms of AS frequently results in disease progression before correct therapy can begin, reducing the efficacy of existing medicines.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Drug Class, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Companies Covered

AbbiVie, Inc, Amgen, Inc, Eli Lilly and Company, Izana Biosciences, Johnson and Johnson Services, Inc, Merck and Co., Inc, Novartis AG, Pfizer, Inc, UCB, Inc, Zydus Lifescience Ltd. and others.

Ankylosing Spondylitis Market Segmentation:

By Drug Class: Based on the Drug Class, Global Ankylosing Spondylitis Market is segmented as; Non-Steroidal Anti-Inflammatory Drug (NSAID), TNF Inhibitors.

By Distribution Channel: Based on the Distribution Channel, Global Ankylosing Spondylitis Market is segmented as; Hospital Pharmacy, Retail Pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2551

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Ankylosing Spondylitis Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Ankylosing Spondylitis Market

7. Global Ankylosing Spondylitis Market, By Drug Class (USD Million) 2021-2034

7.1. Non-Steroidal Anti-inflammatory Drug (NSAID)
7.2. TNF inhibitors
- 7.2.1. Humira
- 7.2.2. Simponi
- 7.2.3. Remicade
- 7.2.4. Enbrel
- 7.2.5. Cimzia

8. Global Ankylosing Spondylitis Market, By Distribution Channel (USD Million) 2021-2034

8.1. Hospital Pharmacy
8.2. Retail Pharmacy

9. Global Ankylosing Spondylitis Market, (USD Million) 2021-2034

9.1. Global Ankylosing Spondylitis Market Size and Market Share

10. Global Ankylosing Spondylitis Market, By Region, (USD Million) 2021-2034

10.1. Asia-Pacific
- 10.1.1. Australia
- 10.1.2. China
- 10.1.3. India
- 10.1.4. Japan
- 10.1.5. South Korea
- 10.1.6. Rest of Asia-Pacific
10.2. Europe
- 10.2.1. France
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. United Kingdom
- 10.2.6. Rest of Europe
10.3. Middle East and Africa
- 10.3.1. Kingdom of Saudi Arabia
- 10.3.2. United Arab Emirates
- 10.3.3. Qatar
- 10.3.4. South Africa
- 10.3.5. Egypt
- 10.3.6. Morocco
- 10.3.7. Nigeria
- 10.3.8. Rest of Middle-East and Africa
10.4. North America
- 10.4.1. Canada
- 10.4.2. Mexico
- 10.4.3. United States
10.5. Latin America
- 10.5.1. Argentina
- 10.5.2. Brazil
- 10.5.3. Rest of Latin America

11. Company Profile

11.1. AbbiVie, Inc
- 11.1.1. Company details
- 11.1.2. Financial outlook
- 11.1.3. Product summary
- 11.1.4. Recent developments
11.2. Amgen, Inc
- 11.2.1. Company details
- 11.2.2. Financial outlook
- 11.2.3. Product summary
- 11.2.4. Recent developments
11.3. Eli Lilly and Company
- 11.3.1. Company details
- 11.3.2. Financial outlook
- 11.3.3. Product summary
- 11.3.4. Recent developments
11.4. Izana Biosciences
- 11.4.1. Company details
- 11.4.2. Financial outlook
- 11.4.3. Product summary
- 11.4.4. Recent developments
11.5. Johnson and Johnson Services, Inc
- 11.5.1. Company details
- 11.5.2. Financial outlook
- 11.5.3. Product summary
- 11.5.4. Recent developments
11.6. Merck and Co., Inc
- 11.6.1. Company details
- 11.6.2. Financial outlook
- 11.6.3. Product summary
- 11.6.4. Recent developments
11.7. Novartis AG
- 11.7.1. Company details
- 11.7.2. Financial outlook
- 11.7.3. Product summary
- 11.7.4. Recent developments
11.8. Pfizer, Inc
- 11.8.1. Company details
- 11.8.2. Financial outlook
- 11.8.3. Product summary
- 11.8.4. Recent developments
11.9. UCB, Inc
- 11.9.1. Company details
- 11.9.2. Financial outlook
- 11.9.3. Product summary
- 11.9.4. Recent developments
11.10. Zydus Lifescience Ltd
- 11.10.1. Company details
- 11.10.2. Financial outlook
- 11.10.3. Product summary
- 11.10.4. Recent developments
11.11. Others